Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
79 results about "Antithrombins" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins.
Anticoagulant fusion protein anchored to cell membrane
InactiveUS6423316B1Prolong clotting timeGood curative effectFungiVirusesCell membraneBlood coagulations
The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).
Owner:IMPERIAL INNOVATIONS LTD
Methods of coating a device using anti-thrombin heparin
Novel conjugates of glycosaminoglycans, particularly heparin and dermatan sulfate, and amine containing species and therapeutic uses thereof are described. In particular, mild methods of conjugating heparins to proteins, such as antithrombin III and heparin cofactor II, which provide covalent conjugates which retain maximal biological activity are described. Uses of these conjugates to prevent thrombogenesis, in particular in lung airways, such as found in infant and adult respiratory distress syndrome, and on surfaces in contact with blood are also described.
Owner:MCMASTER UNIV
Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation
Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the steps of N-deacetylation / N-sulfation, C5 epimerization, O-oversulfation, selective O-desulfation, 6-O-sulfation, N-sulfation, and optional depolymerization, in which said epimerization is performed with the use of the enzyme glucoronosyl C5 epimerase in solution or in immobilized form in the presence of divalent cations. New, particularly interesting antithrombin compounds are obtained by controlling the reaction time in the selective O-desulfation step and submitting the product obtained at the end of the final N-sulfation step to depolymerizazion.
Owner:ORESTE PASQUA +1
Lubricious or/and wettable or/and Anti-thrombin elastomeric gland materials in luer activated devices
InactiveUS20070012893A1Improve wettabilityAvoid clotsMedical devicesCouplingsElastomerClot formation
An elastomeric gland is provided for a luer activating device (LAD). and comprises a unique lubricant and / or wetting agent and / or anti-clotting agent incorporated into the elastomer gland during raw material formulation, calendar blending / molding / curing to deliver the surface lubricity and / or wettability and / or avoid slit plane re-knitting and / or gland induced valve stick down of such devices Functional additive chemistries are selected in terms of generated functional performance level, thermal stability against processing, molecular migratability, molecular weight and elastomer substrate of interest. These additives could include lubricants like chemically modified silicone oils and / or wetting agents like silicone-based surfactant. Elastomer gland with wetting agent would ease fluid path priming and minimize micro air bubble adherence to gland surface. Additives may also include anti-clotting agents intended to reduce potential for clot formation within the fluid path and interstitial space of the valve during blood sampling and infusion.
Owner:BAXTER INT INC +1
Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation
InactiveUS8227449B2High activityReduce bleeding riskBiocideOrganic active ingredientsAntithrombotic AgentSulfation
Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the steps of N-deacetylation / N-sulfation, C5 epimerization, O-oversulfation, selective O-desulfation, 6-O-sulfation, N-sulfation, and optional depolymerization, in which said epimerization is performed with the use of the enzyme glucoronosyl C5 epimerase in solution or in immobilized form in the presence of divalent cations. New, particularly interesting antithrombin compounds are obtained by controlling the reaction time in the selective O-desulfation step and submitting the product obtained at the end of the final N-sulfation step to depolymerization.
Owner:GLYCORES 2000 SRL
Glycosaminoglycans derived from k5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation
InactiveUS20110281820A1High activityReduce bleeding riskOrganic active ingredientsBiocideSulfationAntithrombotic Agent
Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the steps of N-deacetylation / N-sulfation, C5 epimerization, O-oversulfation, selective O-desulfation, 6-O-sulfation, N-sulfation, and optional depolymerization, in which said epimerization is performed with the use of the enzyme glucoronosyl C5 epimerase in solution or in immobilized form in the presence of divalent cations. New, particularly interesting antithrombin compounds are obtained by controlling the reaction time in the selective O-desulfation step and submitting the product obtained at the end of the final N-sulfation step to depolymerization.
Owner:GLYCORES 2000 SRL
Antithrombin activity assay reagent and preparation method and application thereof
InactiveCN106153612AImprove detection stabilityGood detection repeatabilityMaterial analysis by observing effect on chemical indicatorColor/spectral properties measurementsAntithrombin ActivityReagent
The invention discloses a reagent for detecting antithrombin activity, including reagent 1 and reagent 2, wherein: reagent 1 is a chromogenic substrate of FXa, and reagent 2 is a diluent containing FXa and heparin; wherein the chromogenic substrate of FXa is selected from From the following: CH 3 SO 2 ‑D‑Leu‑Gly‑Arg‑p‑nitroanilide·AcOH; CH 3 OCO‑D‑CHG‑Gly‑Arg‑p‑nitroanilide·AcOH; CH 3 OCO‑D‑CHA‑Gly‑Arg‑p‑nitroanilide AcOH; Benzoyl‑Ile‑Glu‑Gly‑Arg‑p‑nitroanilide HCl; Suc‑Ile‑Glu(γ‑Piperidyl)‑Gly‑Arg‑p‑nitroanilide HCl; N-α-Z-D-Arg-Gly-Arg-p-nitroanilide 2HCl; Boc-D-Arg-Gly-Arg-p-nitroanilide 2HCl; Acetyl-D-Arg-Gly-Arg-p ‑nitroanilide·2HCl; 4‑Nz‑D‑Arg‑Gly‑Arg‑p‑nitroanilide·2HCl; 4‑Mbs‑D‑Arg‑Gly‑Arg‑p‑nitroanilide·2HCl. The invention has good detection stability and repeatability, high sensitivity and accuracy, can accurately reflect the activity of antithrombin, and can find patients with abnormal antithrombin activity in the body, thereby providing a basis for treatment.
Owner:SHANGHAI VASCUTECH DIAGNOSIS CO LTD
Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
InactiveUS20110070167A1Avoid problemsFunction increaseBiocideOrganic active ingredientsIsrapafantAntithrombins
ATIII is a serine proteinase inhibitor (serpin) with anti-coagulant, anti-inflammatory, anti-proliferative and anti-angiogenic properties. The invention features methods of treating a subject having lung injury due to burns and smoke inhalation by administering a synergistic combination of antithrombin III and heparin through pulmonary delivery means.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Method for preparing antithrombin
ActiveCN102977207AGood ability of alkali treatmentReduce dosagePeptide preparation methodsProtease inhibitorsBlood plasmaVirus inactivation
The invention provides a method for preparing antithrombin, which comprises the following steps of: (a) precipitation and dissolution; (b) PEG precipitation; (c) virus inactivation; (e) demodulation; (h) adsorption of residual heparin; (i) virus inactivation; and (j) bacterium removal sub-packing and freeze-drying. Through the invention, the hard silica gel matrix (HeparinHyperD) with higher chemical stability is subjected to heparin affinity chromatography; the matrix has better ability against alkali resistance, and is more suitable for needs of industrial production; and the inventor improves the purification technology and the virus inactivation removal and conducts organic combination to expect deep comprehensive utilization of blood plasma and improve the effectiveness and safety of the AT-III preparation, thereby providing a new option to clinical treatment.
Owner:CHENGDU RONGSHENG PHARMA
Method of producing recombinant antithrombin III composition
The present invention provides a process for producing an antithrombin III composition comprising an antithrombin III molecule having complex type N-glycoside-linked sugar chains, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains.
Owner:KYOWA HAKKO KIRIN CO LTD
Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation
InactiveUS20050215518A1Reduce bleeding riskHigh activityBiocideOrganic active ingredientsAntithrombotic AgentSulfation
Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the steps of N-deacetylation / N-sulfation, C5 epimerization, O-oversulfation, selective O-desulfation, 6-O-sulfation, N-sulfation, and optional depolymerization, in which said epimerization is performed with the use of the enzyme glucoronosyl C5 epimerase in solution or in immobilized form in the presence of divalent cations. New, particularly interesting antithrombin compounds are obtained by controlling the reaction time in the selective O-desulfation step and submitting the product obtained at the end of the final N-sulfation step to depolymerizazion.
Owner:ORESTE PASQUA +1
A rapid antithrombin III detecting kit based on interaction between thrombin and a chromogenic substrate and a detecting method thereof
InactiveCN105466920AImprove legibilityEasy to operateMaterial analysis by observing effect on chemical indicatorChromogenic SubstratesColor reaction
The invention belongs to the field of biological medicine in-vitro diagnosis, and particularly relates to a rapid antithrombin III detecting kit based on interaction between thrombin and a chromogenic substrate and a detecting method thereof. The kit comprises R1 reagents, an R2 reagent, a stop buffer and a chromogenic measuring card. The R2 reagent comprises a chromogenic substrate reagent. The chromogenic measuring card is provided with a colorimetric reference belt and a reaction cell. The colorimetric reference belt is provided with six color zones which have colors from deep to light and are respectively corresponding to 20%, 40%, 60%, 80%, 100% and higher than 100% of activity of the antithrombin III. Naked-eye distinctiveness of a chromogenic reaction is improved by improving a formula of the chromogenic substrate and the activity of the antithrombin III and colors distinguishable with naked eyes are correlated to obtain the colorimetric reference belt distinguishable by human eyes, and therefore the activity of the antithrombin III can be rapidly and semiquantitatively detected only by naked-eye determination without the need of using matched instruments.
Owner:鲁翌
Compositions and methods for cell transplantation
InactiveUS20130302291A1Easy to returnEffective and safe combinationOrganic active ingredientsBiocideBiologyBivalirudin
The present invention relates to compositions and methods for cell transplantation. In particular, the present invention provides a composition comprising procoagulant cells and at least one antithrombin activator, preferably unfractionated heparin, as well as at least one thrombin inhibitor, preferably bivalirudin.
Owner:UNIVERSITE CATHOLIQUE DE LOUVAIN
Heparin compositions that inhibit clot associated coagulation factors
InactiveUS20080119438A1Prevent reactivationAvoid generatingOrganic active ingredientsBlood disorderVenous bloodAngina
The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by administering an agent which, inter alia, is capable of (1) inactivating fluid-phase thrombin and thrombin which is bound either to fibrin in a clot or to some other surface by catalyzing antithrombin; and (2) inhibiting thrombin generation by catalyzing factor Xa inactivation by antithrombin III (ATIII). The compositions and methods of the present invention are particularly useful for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infraction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.
Owner:WEITZ JEFFREY I +1
Method for preparing highly-active thrombin inhibitor
InactiveCN1840187AStrong antithrombin activitySignificant effectPeptide/protein ingredientsVector-based foreign material introductionCurative effectThrombin activity
The invention relates to a process for preparing high activity thrombin inhibitors, which comprises subjecting hirudin, the natural specific inhibitor of thrombin to DNA family restructuring, carrying out restructuring to hirudin HV1, HV2, HV3 genes, constructing reorganization library for hirudin bacteriophage display, using thrombin as coating antigen, subjecting bacteriophage reorganization library to three rounds of enriched elutriation including adsorption, elution and expansion, obtaining a plurality of bacteriophage monoclons with high affinity with thrombin through ELISA screening, carrying out pronucleus induced expression to these clones, finally detecting the antithrombogenic activity of the purification expression product.
Owner:龙铟 +1
Novel medicament for treating cardio-cerebrovascular diseases and preparation method
InactiveCN102793734AAchieving a good effect of treating both symptoms and root causesFully absorbedAnthropod material medical ingredientsMetabolism disorderDiseaseFreeze-drying
The invention relates to a novel medicament for treating the cardio-cerebrovascular diseases and a preparation method and belongs to the technical field of preparation of the novel medicament for treating the cardio-cerebrovascular diseases. According to the invention, blood-sucking leeches, panax pseudoginseng and earthworm are used as raw materials. According to the invention, by a special preparation process of carrying out liquid nitrogen flash freezing, low-temperature superfine grinding and freeze drying before sterilization on the raw materials, the grinding fineness can reach 1 to 10 micrometers, the active ingredients of the blood-sucking leeches can be stored to the greatest extent, the active ingredients can be sufficiently adsorbed by a patient, and the novel medicament has comprehensive effects of promoting circulation, removing stasis, resisting to coagulation, reducing the pressure, lowering lipid, resisting to platelet aggregation and dissolving thrombi and is safe and reliable to take. The invention solves the problems that an existing medicament which uses leeches as the raw materials and is used for treating the cardio-cerebrovascular diseases adopts non blood-sucking leeches as the medicine and adopts a conventional grinding method, so that the antithrombase effect is poor and the curative effect is influenced; and enteric capsules only adopt the single medicine of blood-sucking leech and have poor effects of reducing the pressure, lowering the lipid and dissolving the thrombi and the preparation process ensures the active ingredients of the leeches not to be completely stored and is unbeneficial for a patient to adsorb the active ingredients.
Owner:龚元
Light-emitting diode (LED) phototherapy oxygenation type haemodialysis machine
InactiveCN102133438AFunction increaseEnhance immune functionDialysis systemsLight therapyExtracorporeal circulationDisease
The invention discloses a light-emitting diode (LED) phototherapy oxygenation type haemodialysis machine, which is applied to haemodialysis ultra-filtration for treating diseases of acute renal failure, chronic renal failure, uremia, hypertension, arteriosclerosis, blood hyperviscosity, histanoxia and the like and belongs to the field of medical instruments. The LED phototherapy oxygenation type haemodialysis machine mainly comprises an LED phototherapy oxygenation part device, a blood extracorporeal circulation pipeline, a dialysate supply water pipeline and a circuit controlled by a microcomputer. The machine is characterized in that: the LED phototherapy oxygenation part device is embedded into an arterial cup clamper and a dialyser clamper of the blood extracorporeal circulation pipeline by a plurality of small-sized LED multi-wavelength penetration nails. In the process of haemodialysis, part of or all of lamps in the LED phototherapy oxygenation device can operate according to a specific situation for carrying out on-line irritation on blood in the circulation pipeline by utilizing a principle of strong penetrating power of LED multi-wavelength, so that blood circulation can be improved, agglutination of erythrocytes, platelet aggregation and blood viscosity are reduced, the flow rate of blood is improved, antithrombin is activated, the content of thrombin is reduced, coagulation and hemostasis mechanisms are adjusted, and the aim of treatment is achieved.
Owner:鲁广洲
Glycosaminoglycans derived from k5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation
InactiveUS20090105192A1Improved and selective antithrombin activityReduce bleeding riskOrganic active ingredientsBiocideAntithrombotic AgentSulfation
Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the steps of N-deacetylation / N-sulfation, C5 epimerization, O-oversulfation, selective O-desulfation, 6-O-sulfation, N-sulfation, and optional depolymerization, in which said epimerization is performed with the use of the enzyme glucoronosyl C5 epimerase in solution or in immobilized form in the presence of divalent cations. New, particularly interesting antithrombin compounds are obtained by controlling the reaction time in the selective O-desulfation step and submitting the product obtained at the end of the final N-sulfation step to depolymerization.
Owner:ORESTE PASQUA +1
Protective agent of human antithrombin preparation in freezing and drying process
ActiveCN102973526AHigh activityLittle loss of activityPowder deliveryPeptide/protein ingredientsSucroseFreeze-drying
The invention discloses a protective agent of human antithrombin preparation in freezing and drying process. According to the protective agent, a protective agent solution is prepared from one of solute sucrose, amino acid or salt of the amino acid by using deionized water, wherein the amino acid is lysine or hydrochloride in the salt of the lysine, or tyrosine or one of the salts in the tyrosine, or aspartic acid or one of the salts in the aspartic acid; one of the solutes is prepared into a solution by using deionized water so as to obtain the protective agent; the protective agent is added before the human antithrombin preparation is frozen and dried, the inactivation of the main antithrombin ingredient in the preparation in the freezing and drying process is effectively prevented, the activity of the antithrombin is protected, and the antithrombin has better forming appearance and redissolving clarity of the preparation after being frozen and dried.
Owner:GUIZHOU TAIBANG BIOLOGICAL PROD
Transgenically produced antithrombin III
InactiveUS20080176786A1Peptide/protein ingredientsAntipyreticMonosaccharide compositionPlasma derived
This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid / N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.
Owner:GTC BIOTHERAPEUTICS INC
Electrochemiluminescence kit for detecting TAT (thrombin-antithrombin complex) and preparation method
PendingCN111007250AAchieve accurate quantificationHigh detection sensitivityChemiluminescene/bioluminescenceBiological material analysisAntiendomysial antibodiesLuminophore
The invention relates to an electrochemiluminescence kit for detecting a novel thrombus marker TAT (thrombin-antithrombin complex) in blood and a preparation method of the electrochemiluminescence kit. The prepared kit comprises a streptavidin coupled magnetic particle working solution, a biotin labeled thrombin antibody working solution, a terpyridyl ruthenium labeled antithrombin antibody working solution, a TAT calibrator and / or quality control substance working solution, a tripropylamine-containing electrochemiluminescence substrate solution and a cleaning solution. A luminescence system of the kit is electrochemiluminescence, a streptavidin-biotin signal amplification system is utilized, the detection sensitivity is high, the linear range is wide, the detection result repeatability ishigh, and accurate quantification of the thrombin-antithrombin compound can be achieved.
Owner:江苏三联生物工程股份有限公司
Reagent and method for measuring thrombin-antithrombin complex
ActiveUS20180238871A1Small amountAccurate measurementDisease diagnosisBiological testingDextranAmmonium chloride mixture
Owner:MITSUBISHI CHEM MEDIENCE
Antithrombin preparation and preparation method thereof
The invention relates to an antithrombin enteric soft capsule preparation which is prepared by using part or all of leech, bloodsucker, whitmania acranulata Whitman, hirudinaria manillensis, dinobdella ferox, Haemadipsa japonica Whitman and Haemadipsa sylvestris as raw materials and other pharmaceutically acceptable auxiliary materials. The preparation method comprises the steps of: 1, preparing powder for preparation; 2, preparing contents in teh soft capsule; and 3, preparing the tenteric soft capsule. The preparation process for the enteric soft capsule preparation has the advantages of improving the stability, improving the transfer rate of effective components, lowering the production stroage requirements, reducing the process difficulty, and has the positive meanings on increasing the stability, quickening the development of the soft capsule preparations, improving the quality, and lowering the production cost.
Owner:GUIZHOU XINBANG PHARMACEUTICAL CO LTD
Use of antithrombin in the treatment of pre-eclampsia
In one aspect, the disclosure provides methods for the treatment of pre-eclampsia and severe pre-eclampsia comprising administering antithrombin. In some embodiments, the antithrombin used in the methods disclosed herein is ATryn®.
Owner:GTC BIOTHERAPEUTICS INC
Instrument for capturing free thrombi
The purpose of the present invention is to provide an instrument for capturing free thrombi, which can inhibit a blood coagulation reaction at a primary hemostasis stage in which platelet is involved or a coagulated thrombi formation stage in which a blood coagulation factor is involved, whereby it becomes possible to secure the capture of free thrombi and to prolong the usable time of the instrument. The present invention provides: an instrument for capturing free thrombi, in which a compound having an anti-thrombin capability is immobilized on the surface thereof; and a method for capturing free thrombi, which comprises capturing free thrombi in blood in vivo using the instrument for capturing free thrombi.
Owner:井上宽治 +1
Modified low molecular weight heparin that inhibits clot associated coagulation factors
InactiveUS20050032745A1Prevent reactivationPacify thrombusOrganic active ingredientsVenous bloodAngina
The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by administering an agent which, inter alia, is capable of (1) inactivating fluid-phase thrombin and thrombin which is bound either to fibrin in a clot or to some other surface by catalyzing antithrombin; and (2) inhibiting thrombin generation by catalyzing factor Xa inactivation by antithrombin III (ATIII). The compositions and methods of the present invention are particularly useful for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infarction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.
Owner:HAMILTON CIVIC HOSPITALS RESARCH DEV
Heparin compositions that inhibit clot associated coagulation factors
The present invention provides compositions and methods for treating cardiovascular disease. More specifically, the invention relates to thrombin by administering, inter alia, capable of (1) inactivating thrombin in the fluid phase by catalytic antithrombin and either binding to fibrin in a clot or binding to some other surface; and (2) Substances that inhibit thrombin production by antithrombin III (ATIII) catalyzing factor Xa inactivation to alter thrombus formation. The compositions and methods of the present invention are particularly useful for the prevention of thrombosis in cardiac bypass circulation and in patients undergoing renal dialysis, and for the treatment of patients with, or at risk of, cardiovascular disease associated with thrombosis In patients with thrombosis-related cardiovascular diseases such as unstable angina, acute myocardial infarction (heart attack), cerebrovascular accident (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.
Owner:HAMILTON CIVIC HOSPITALS RESARCH DEV
Preparation method for human antithrombin III
InactiveCN105315365AReduce the probability of activationImprove pass ratePeptide preparation methodsProtease inhibitorsUltrafiltrationPolyethylene glycol
The invention discloses a preparation method for human antithrombin III (AT-III). The preparation method comprises the following steps: (1) precipitation and dissolution of a blood plasma fraction IV; (2) polyethylene glycol (PEG) precipitation and impure protein removing; (3) DEAE Sephadex A-50 gel adsorption; (4) S / D virus inactivation; (5) heparin affinity column chromatography; (6) ultrafiltration and concentration; (7) addition of a stabilizer and regulation; (8) nanofilm virus-removing filtration; (9) sterilizing filtration; (10) freeze-drying; (11) dry and fever virus inactivation. According to the preparation method, blood coagulation factors, which remain in the raw materials and are depended by vitamin K, are removed, so as to greatly lower the possibility of protein activation in the production process, and improve the product qualification ratio; PEG is adopted for the impure protein removing, so as to reduce the load of a chromatographic column; a liquid obtained from lyophilized powder re-dissolution is clear, transparent, and free of protein precipitation and opalescence; through adoption of a three-step virus inactivation method, the safety of human AT-III for clinical use can be greatly improved.
Owner:上海洲跃生物科技有限公司
Protein chip for combined detection of multiple thrombus markers
PendingCN111024941ALow costRealize automated detectionDisease diagnosisBiological testingDimerFibrinogen degradation product
The invention discloses a protein chip for combined detection of multiple thrombus markers. A preparation method of the protein chip comprises the following steps: (1) black slide pretreatment; (2) antibody solution sample application; (3) a sealing process; and preparation of the protein chip. The protein chip is used for detecting concentrations of various thrombus markers, preventing and reducing thrombus risks and guiding thrombus treatment. The product disclosed by the invention is a protein chip diagnostic kit comprising six indexes of TAT (thrombin-antithrombin complex), PIC (plasmin-alpha2 anti-plasminogen complex), tPAIC (tissue-type plasminogen activator-plasminogen activation inhibition complex), TM (thrombomodulin), FDP (fibrinogen degradation product) and DD (D-dimer). The indexes are detected by using a protein chip technology for the first time, and the method has the advantages of quickness, high efficiency, simplicity, convenience, low cost and the like.
Owner:江苏三联生物工程股份有限公司
Compositions and methods for cell transplantation
InactiveUS20170042940A1Effective and safe combinationAvoid harmful effectsOrganic active ingredientsPeptide/protein ingredientsCells transplantationUnfractioned heparin
The present invention relates to compositions and methods for cell transplantation. In particular, the present invention provides a composition comprising procoagulant cells and at least one antithrombin activator, preferably unfractionated heparin, as well as at least one thrombin inhibitor, preferably bivalirudin.
Owner:UNIVERSITE CATHOLIQUE DE LOUVAIN
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com